Hinge Health's Q2 Loss Widens to $55.2M Amid Revenue Growth

TL;DR

**Hinge Health is burning cash faster than it's growing, making it a risky bet despite revenue gains.**

AI Summary

Hinge Health, Inc. reported a net loss of $55.2 million for the three months ended June 30, 2025, a significant increase from the $40.1 million net loss in the prior-year period. Revenue for the three months ended June 30, 2025, was $120.5 million, up 35% from $89.3 million in the same period of 2024. The company's accumulated deficit grew to $850.3 million as of June 30, 2025, from $795.1 million at March 31, 2025. Operating expenses increased, with Research and Development rising to $30.1 million from $25.5 million year-over-year, and General and Administrative expenses increasing to $28.7 million from $22.1 million. Hinge Health completed an IPO of Series E Preferred Stock in Q2 2025, raising capital, and also issued Common Class B shares in May 2025. The company continues to invest heavily in growth and product development, as evidenced by the increased R&D spend and the expansion of its equity incentive plan. The company's strategic outlook focuses on expanding its digital musculoskeletal care platform, despite ongoing losses.

Why It Matters

Hinge Health's widening net loss of $55.2 million, despite a 35% revenue increase to $120.5 million, signals a critical juncture for investors. While revenue growth is positive, the escalating losses raise questions about the path to profitability and the sustainability of its current burn rate. For employees, continued investment in R&D and expansion could mean job security and growth opportunities, but persistent losses could also lead to future restructuring. Customers benefit from ongoing product development and platform expansion, enhancing the value of Hinge Health's digital musculoskeletal care. In the competitive digital health market, Hinge Health's ability to convert revenue growth into profitability will determine its long-term viability against rivals like Teladoc Health and Omada Health.

Risk Assessment

Risk Level: high — The company reported a net loss of $55.2 million for the three months ended June 30, 2025, a significant increase from the $40.1 million net loss in the prior-year period. Its accumulated deficit reached $850.3 million as of June 30, 2025, indicating a sustained history of unprofitability and a high cash burn rate, which poses a substantial risk to future operations and investor capital.

Analyst Insight

Investors should exercise caution and closely monitor Hinge Health's path to profitability. While revenue growth is encouraging, the increasing net losses and accumulated deficit suggest a need for a clear strategy to reduce operating expenses or accelerate revenue growth to offset losses. Consider waiting for signs of improved financial efficiency before investing.

Financial Highlights

revenue

$120.5M

net Income

-$55.2M

revenue Growth

+35%

Executive Compensation

Key Numbers

• $120.5M — Revenue (for the three months ended June 30, 2025, up 35% year-over-year)
• $55.2M — Net Loss (for the three months ended June 30, 2025, widened from $40.1M in 2024)
• $850.3M — Accumulated Deficit (as of June 30, 2025, increased from $795.1M at March 31, 2025)
• $30.1M — Research and Development Expense (for the three months ended June 30, 2025, up from $25.5M in 2024)
• $28.7M — General and Administrative Expense (for the three months ended June 30, 2025, up from $22.1M in 2024)
• 35% — Revenue Growth (year-over-year for the three months ended June 30, 2025)

Key Players & Entities

• Hinge Health, Inc. (company) — filer of the 10-Q
• James Pursley (person) — Chief Executive Officer
• Coatue Growth Fund IV, L.P. (company) — investor in Common Class A shares
• SEC (regulator) — recipient of the 10-Q filing
• 06 Technology (company) — organization name associated with the filer
• Montreal, Canada (location) — location of operations or business activity
• San Francisco, CA (location) — business headquarters

FAQ

Risk Factors

• Sustained Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $55.2 million for Q2 2025, an increase from $40.1 million in the prior year. The accumulated deficit grew to $850.3 million as of June 30, 2025. This trend indicates ongoing unprofitability and a significant reliance on external funding to sustain operations.
• High Operating Expense Growth [medium — operational]: Research and Development expenses increased to $30.1 million from $25.5 million year-over-year, and General and Administrative expenses rose to $28.7 million from $22.1 million. While indicative of investment in growth, this rapid increase in operating costs outpaces revenue growth and contributes to widening losses.
• Dependence on Capital Raising [high — financial]: Hinge Health completed an IPO of Series E Preferred Stock in Q2 2025 and issued Common Class B shares in May 2025, demonstrating a reliance on equity financing to fund its operations and growth initiatives. Future capital needs and the ability to secure additional funding remain critical.
• Competitive Digital Health Landscape [medium — market]: The company operates in the competitive digital musculoskeletal care market. Continued investment in product development and platform expansion is necessary to maintain market share and differentiate from competitors.

Industry Context

Hinge Health operates in the rapidly growing digital musculoskeletal (MSK) health market. This sector is characterized by increasing demand for virtual care solutions, driven by rising healthcare costs and the need for convenient, accessible treatment options. The competitive landscape includes numerous startups and established healthcare providers vying for market share through innovative technology and service offerings.

Regulatory Implications

As a digital health provider, Hinge Health must navigate complex regulatory environments, including data privacy laws (like HIPAA in the US) and regulations governing telehealth services. Compliance with these evolving standards is crucial to avoid penalties and maintain patient trust. Changes in healthcare policy or reimbursement models could also significantly impact the company's business operations and financial performance.

What Investors Should Do

1. Monitor path to profitability
2. Assess effectiveness of growth investments
3. Evaluate future capital needs

Key Dates

• 2025-06-30: End of Q2 2025 — Reporting period for the 10-Q, showing increased revenue but also a wider net loss and growing accumulated deficit.
• 2025-05-01: Issuance of Common Class B shares — Indicates ongoing equity financing activities to support company operations and growth.
• 2025-06-30: IPO of Series E Preferred Stock — Successful capital raise event, providing funds for continued investment in growth and product development.
• 2025-06-30: Accumulated Deficit reached $850.3 million — Highlights the company's long-term unprofitability and reliance on capital infusions.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical unprofitability and the extent to which it has relied on external funding.)

Series E Preferred Stock

A class of preferred stock issued by Hinge Health, likely representing a significant round of private equity financing. (The IPO of this stock signifies a major capital-raising event for the company.)

Common Class B Shares

A class of common stock, often with different voting rights or other characteristics compared to Class A shares. (The issuance of these shares indicates ongoing equity transactions and potential changes in ownership structure.)

Equity Incentive Plan

A plan established by a company to grant stock options, restricted stock units, or other equity awards to employees. (Shows the company's strategy for compensating and retaining talent through stock-based awards, contributing to R&D and operational growth.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Hinge Health demonstrated strong revenue growth of 35% for the three months ended June 30, 2025, reaching $120.5 million. However, this top-line growth was accompanied by a significant increase in net loss, which widened from $40.1 million to $55.2 million. Operating expenses, particularly in Research and Development and General and Administrative functions, also saw substantial year-over-year increases, contributing to the wider loss. The accumulated deficit continued to grow, underscoring the company's ongoing investment in expansion and product development at the expense of near-term profitability.

Key Financial Figures

• $0.00001 — tered Class A Common Stock, par value $0.00001 per share HNGE The New York Stock E

Filing Documents

• hnge-20250630.htm (10-Q) — 3984KB
• hnge-ex10_7.htm (EX-10.7) — 107KB
• hnge-ex31_1.htm (EX-31.1) — 17KB
• hnge-ex31_2.htm (EX-31.2) — 16KB
• hnge-ex32_1.htm (EX-32.1) — 11KB
• hnge-ex32_2.htm (EX-32.2) — 11KB
• 0000950170-25-106577.txt ( ) — 13842KB
• hnge-20250630.xsd (EX-101.SCH) — 1399KB
• hnge-20250630_htm.xml (XML) — 2839KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements Of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39 PART II. OTHER INFORMATION 41 Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 92 Item 3. Defaults Upon Senior Securities 93 Item 4. Mine Safety Disclosures 93 Item 5. Other Information 93 Item 6. Exhibits 95

Signatures

Signatures 96 i CAUTIONARY NOTE REG ARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the three months ended June 30, 2025 (this "Quarterly Report") contains "forward-looking statements" within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements established by Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact contained in this Quarterly Report, and generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential" "predict," "project," "should," "target," or "will," or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about: our ability to attract and retain clients; our ability to attract, enroll, and retain members; our ability to attract and retain relationships with partners; our ability to estimate the size of our target market; the demand for musculoskeletal ("MSK") pain treatment and prevention solutions in general, and the demand for our platform in particular; our ability to enhance our platform and programs or develop new programs, capabilities, features, and products, including our high-performance provider network for MSK care, HingeSelect; our expectations regarding the accepta

—FIN ANCIAL INFORMATION

PART I—FIN ANCIAL INFORMATION

Fin ancial Statements

Item 1. Fin ancial Statements. HINGE HEALTH, INC. CON DENSED CONSOLIDATED BALANCE SHEETS Unaudited ( in thousands, except share and par value data ) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 237,170 $ 300,785 Marketable securities 176,087 165,787 Accounts receivable, net of allowance for credit losses of $ 7,649 and $ 6,470 as of June 30, 2025 and December 31, 2024, respectively 99,299 42,495 Deferred commissions 24,354 18,615 Inventory 13,987 10,873 Prepaid expenses and other current assets 47,528 44,891 Total current assets 598,425 583,446 Goodwill 64,096 61,607 Intangible assets, net 2,961 1,807 Property, equipment and software, net 7,724 7,380 Operating lease right-of-use assets 8,605 9,607 Other assets 11,843 9,412 Total assets $ 693,654 $ 673,259 Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Current liabilities: Accounts payable and accrued liabilities $ 34,898 $ 27,853 Operating lease liabilities 4,047 3,814 Deferred revenue 275,138 217,632 Total current liabilities 314,083 249,299 Operating lease liabilities, noncurrent 5,919 7,258 Total liabilities 320,002 256,557 Commitments and Contingencies (Note 6) Redeemable convertible preferred stock: Redeemable convertible preferred stock, $ 0.00001 par value; 4,330,341 shares of Series E authorized, 2,581,837 shares of Series E preferred stock issued and outstanding as of June 30, 2025, 48,190,771 shares authorized and 48,150,146 shares issued and outstanding as of December 31, 2024; aggregate liquidation preference of $ 200,000 and $ 845,478 as of June 30, 2025 and December 31, 2024, respectively 199,874 851,272 Stockholders' equity (deficit): Class A common stock, $ 0.00001 par value: 1,000,000,000 shares authorized as of June 30, 2025; 26,909,512 shares issued and out

View Full Filing

View this 10-Q filing on SEC EDGAR